IO Biotech, Inc. IOBT 深 滬
已收盤 08-01 16:00:00 美东时间
2.22
-0.010
-0.45%
華盛通- 最 高2.25
- 今 開2.19
- 成交量 19.26万股
- 最 低 2.10
- 昨 收 2.23
- 總市值 1.46亿
- 52周最高 2.4773
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 0.66
- 委 比 47.83%
- 總股本 6588.09万
- 歷史最高 17.88
- 量 比 0.22
- 振 幅 6.73%
- 歷史最低 0.66
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IO Biotech Elects New Director at Annual Meeting
The latest update is out from IO Biotech ( ($IOBT) ). On June 5, 2025, IO Biote...
06-10 05:17
IO Biotech Files For For Resale Of Up To 5,623,664 Shares By Selling Stockholders
-SEC Filing
05-24 04:09
IO Biotech Q1 EPS $(0.34) Beats $(0.38) Estimate
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the
05-14 20:15
美股大行评级 | 富国银行：维持艾伯维"超配"评级，目标价从210美元升至240美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持AnaptysBio(ANAB)"超配"评级，目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20
IO Biotech Secures €57.5 Million EIB Loan Facility
The latest announcement is out from IO Biotech ( ($IOBT) ). IO Biotech has secu...
2024-12-20 21:27
IO Biotech Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
2024-11-13 00:20
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
2024-09-18 20:40
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Shares of Exicure, Inc. (NASDAQ:XCUR) rose sharply in today's pre-market tradin...
2024-09-16 18:07
快讯 | IO Biotech宣布IO102-IO103在爱文思控股一线治疗晚期头颈部癌症的二期试验取得积极结果
IO Biotech Announces Positive Results From Phase 2 Trial of IO102-IO103 in the ...
2024-09-14 14:30
Optimistic Outlook on IO Biotech’s PFS Improvements Despite ORR Setback
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy ...
2024-09-03 18:15
